29.04 
0.07(0.24%) 25 May 04:00 SGT|After Hours
:
29.02 0.02 (0.07%) 25 May 07:32 SGT
| Prev Close: | 29.11 |
|---|
| Open: | 28.90 |
|---|
| Bid: | 28.77 x 300 |
|---|
| Ask: | 29.95 x 200 |
|---|
| 1y Target Est: | 31.57 |
|---|
| Beta: | 0.81 |
|---|
| Next Earnings Date: | 29-Jul-13 |
|---|
| Day's Range: | 28.68 - 29.11 |
|---|
| 52wk Range: | 21.40 - 31.15 |
|---|
| Volume: | 35,082,013 |
|---|
| Avg Vol (3m): | 33,862,500 |
|---|
| Market Cap: | 205.99B |
|---|
| P/E (ttm): | 13.90 |
|---|
| EPS (ttm): | 2.09 |
|---|
| Div & Yield: | 0.96 (3.30%) |
|---|
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Final Glance: Pharmaceuticals companiesAP(Sat, 06:03 SGT)
- Midday Glance: Pharmaceuticals companiesAP(Sat, 01:17 SGT)
- Early Glance: Pharmaceuticals companiesAP(Fri, 24 May)
- J&J expects 10-plus new drug applications by 2017AP(Fri, 24 May)
- Ireland says will not be U.S. 'whipping boy' on taxReuters(Thu, 23 May)
- Ireland says will not be U.S. "whipping boy" on taxReuters(Thu, 23 May)
- Ireland says will not be U.S. "whipping boy" on taxReuters(Thu, 23 May)
- Pfizer plans offering to pare Zoetis stakeAP(Thu, 23 May)
- Correction: Pfizer-Study Halted storyAP(Wed, 22 May)
- Pfizer halts study of non-Hodgkin's lymphoma drugAP(Tue, 21 May)
- Agilent Unit & Pfizer CollaborateZacks(Fri, 15 Feb)
- Data on Biogen Hemophilia CandidatesZacks(Tue, 12 Feb)
- The Zacks Analyst Blog Highlights: Comstock Resources, Pfizer, Actavis, Sanofi and Novo NordiskZacks(Fri, 8 Feb)
- Protalix Exploring OptionsZacks(Fri, 8 Feb)
- Data on Auxilium's XiaflexZacks(Fri, 8 Feb)
Key Statistics
| Forward P/E (1 yr): | 12.36 |
|---|
| P/S (ttm): | 3.58 |
|---|
| Ex-Dividend Date: | 08-May-13 |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | 2.22 |
|---|
| Quarterly EPS Est
(Jun-13)
: | 0.58 |
|---|
| Mean Recommendation*: | 2.0 |
|---|
| PEG Ratio (5 yr expected): | 5.46 |
|---|
Business Summary
Pfizer Inc., a biopharmaceutical company, discovers, develops, manufactures, and sells medicines for people and animals worldwide. Its Primary Care segment offers human prescription pharmaceutical products primarily prescribed by primary-care phys...
View More